In April 2019, Charles River acquired Citoxlab to strengthen its portfolio & geographic footprint, enhancing the ability to partner with clients across the drug discovery and development continuum. This acquisition helped Charles River strengthen its position in regulated safety assessment services, non-regulated discovery services, animal research models, and medical device testing.

Northbrook, IL 60062 -- (SBWire) -- 07/17/2023 --Mice Model Market by Model Types & Services (Inbred Mice, Genetically Engineered Mice), Technology (Microinjection, Nuclear Transfer, CRISPR/CAS9), Application (PDx Models, Drug Discovery), End User (Pharma, Biotech, CROs, CDMOs) - Global Forecast to 2028", is projected to reach USD 2.7 billion by 2028 from USD 1.4 billion in 2023, at a CAGR of 13.9% during the forecast period. Some of the prominent factors driving the growth of this market are advancements in mouse models, and the rising number of clinical trials are boosting the growth of the market. However, the presence of alternative animal research models recent ban on animal models from U.S.FDA can hamper the market growth.

The mice model industry is expected to experience significant growth in the near future as researchers and pharmaceutical companies continue to use mice to study human diseases and develop new treatments. With the emergence of advanced genetic engineering techniques, researchers will be able to create mice models that more accurately replicate human diseases. In addition, the use of CRISPR technology is expected to increase the efficiency and accuracy of mice model research. This could lead to the development of more effective treatments for human diseases. Furthermore, the increasing demand for mouse models for clinical trials and drug discovery is expected to further drive the growth of the mice model industry.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1308

Browse in-depth TOC on "Mice Model Market"
228 - Tables
37 - Figures
223 – Pages

Key Market Players:

The market for mice model is highly consolidated, with key players strategizing to capture the market. Prominent players in the mice model market are Charles River Laboratories (US), The Jackson Laboratory (US), Inotiv (US), genOway (France), Taconic Biosciences, Inc. (US), Janvier Labs (France), Harbour BioMed (China), Trans Genic Inc. (Japan), Ingenious Targeting Laboratory (US), PolyGene AG (Switzerland), Aragen Life Sciences Ltd. (India), Cyagen Biosciences (US), Crown Biosciences (US), TransCure bioServices (France), Ozgene Pty. Ltd. (Australia), The Andersons, Inc. (US), Allentown, LLC (US), Innovive (US), Lab Products, LLC. (US), Crescendo Biologics Limited (UK), ImmunoGenes (Hungary), Lexicon Pharmaceuticals, Inc. (US), Horizon Discovery Ltd (UK). Marshall BioResources (US), and Applied StemCell Inc. (US).

Driver: Increasing penetration of EHRs & health information exchange systems in healthcare organizations
During the last decade, there has been a significant increase in the adoption of EHR systems by healthcare organizations. This can primarily be attributed to the promotion of EHRs and their "meaningful use" for improving the quality of healthcare by federal and state governments as well as insurance providers. With the significant growth in the adoption of EHRs, a large volume of electronic data is generated by healthcare organizations. This data needs to be managed effectively to ensure its optimum utilization for improving the quality of patient care. In this regard, medical device connectivity solutions have proven to be effective and are increasingly being utilized by several healthcare organizations to improve clinical outcomes as well as minimize the overall cost of healthcare. In addition, these solutions enable easy data accessibility, easy flow of patient information to EHR systems, and help in achieving meaningful use of EHR systems by eliminating manual entries, reducing medical errors, and increasing the efficiency of processes.

In the US, the Health Information Technology for Economic and Clinical Health (HITECH) Act, enacted under the American Recovery and Reinvestment Act (ARRA), allocated funding for incentivizing hospitals and physicians who demonstrate meaningful use of EHRs. With the growing regulatory requirements and increasing use of electronic health records, the demand for automated and interoperability solutions is also increasing

The high adoption of EMR solutions and the growing emphasis of governments across various developed and developing countries on building nationwide healthcare information exchanges (HIEs) are expected to increase the demand for efficient medical device connectivity solutions

Restraint: High cost of deployment for small healthcare organizations

The cost of interoperability and connectivity solutions for different medical devices is considerably high. Smaller healthcare organizations struggle to implement internet connectivity to medical devices. This is mainly due to difficulties in implementing multiple networks with health setups, a lack of wireless connectivity options, and the need to install subsequent myriads of security layers to avoid data breaches. Moreover, support and maintenance services, which include modification and upgrading software as per changing user requirements, represent a recurring expenditure, which accounts for a large share of the total cost of ownership. Also, post-sales custom interface development for device integration requires additional verification and validation to ensure solution accuracy and completeness. This further increases the total cost of ownership for healthcare providers. Small hospitals and healthcare organizations cannot afford these additional costs.

Model type segment accounted for the largest share of the mice model market

Among the model type & services, the mice model market is segmented into model type and services. In 2022, the model type segment accounted for the largest share of the mice model market. Growth in this market segment can be attributed to availability of various types of mice models due to advancements in biotechnology.
Cryopreservation services is the fastest-growing application segment of the mice model market
Based on application, the mice model market is segmented into breeding services, cryopreservation services, rederivation services, quarantine services and other services. In 2022, the cryopreservation services segment accounted for the fastest-growing share of the application segment of mice model market. Market growth can largely be attributed to the need of preservation of novel mice models.

Asia Pacific: The fastest-growing region in the mice model market.

The Asia Pacific mice model market is projected to grow at the highest CAGR during the forecast period, mainly due to the rising focus on R&D activities, increasing adoption of mice models, and technological development in R&D activites. Moreover, growth in regenerative medicine and biomedical & medical research in Japan are some of the key factors contributing to market growth in the region. The Asian market has also garnered significant attention from global players due to the comparatively less-stringent regulations in Asian countries as compared to those in Europe and the US, as well as the region's low-cost advantage—both factors have driven outsourcing to Asia.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=1308

Mice Model Market Dynamics:

Drivers:

1. Rising investments in mouse model-based research
2. Increasing demand for mouse-based clinical trials (MCTs)
3. Growing preference for personalized medicine

Restraints:

1. Introduction of 3D-printed mouse models

Opportunities:

1. Utilization of CRISPR in biomedical research

Challenges:

1. Development of alternative animal testing methods

Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=1308

Recent Developments:

- In April 2019, Charles River acquired Citoxlab to strengthen its portfolio & geographic footprint, enhancing the ability to partner with clients across the drug discovery and development continuum. This acquisition helped Charles River strengthen its position in regulated safety assessment services, non-regulated discovery services, animal research models, and medical device testing.

- In June 2020, Charles River Laboratories established two new offices in China and Singapore, combined with its existing locations in Japan, Taiwan, India, and South Korea. These offices support sales and project management for biologics research.

- In January 2022, Inotiv completed the acquisition of Orient BioResource Center, Inc. from Orient Bio, Inc., a preclinical CRO and animal model supplier based in Seongnam, South Korea. Orient BioResource Center is a primate quarantine & holding facility located near Alice, Texas.

Mice Model Market Advantages:

- High-throughput Screening: Mice models provide an efficient platform for high-throughput screening of compounds to identify those with pharmacological activity. This allows for rapid identification of promising compounds that can be further tested in preclinical studies.

- Improved Accuracy: Mice models are more accurate than other animal models because they can be genetically modified to have mutations that are seen in humans. This allows for more precise testing of drug efficacy and safety compared to other animal models.

- Reduced Cost: Mice models are much cheaper than other large animal models. This allows for more cost-effective drug development and testing.

- Reduced Timeframe: Mice models provide faster results than other animal models. This reduces the time required to develop drugs and get them to market.

- Reduced Animal Use: Mice models reduce the number of animals needed for drug testing, reducing the use of animals in research.